Bayer's Billion-Euro April: A Month of Legal and Financial Reckoning

Bayer faces a pivotal Supreme Court hearing on glyphosate lawsuits amid a forecast of €5B negative cash flow for 2026. Key shareholder events and operational stability frame a critical month.

For Bayer, the coming weeks represent a critical convergence of financial pressure and legal fate. The company enters April with its 2026 financial targets publicly intact, but a scheduled Supreme Court hearing and a deeply negative cash flow forecast underscore the immense stakes.

The structural financial challenges are stark. Bayer's free cash flow plummeted by nearly a third in 2025 to approximately €2.1 billion. Management is now planning for a significantly negative free cash flow of around €5 billion for 2026. A primary driver is the expectation of roughly €5 billion in litigation-related outflows this year alone. This cash burn occurs against a backdrop of a net financial debt load nearing €30 billion.

All eyes are now on Washington, D.C., where oral arguments before the U.S. Supreme Court commence on April 27th. The core of Bayer's argument is that federal pesticide law (FIFRA) should preempt state-level cancer warning requirements for its glyphosate-based herbicides. A favorable ruling would fundamentally undercut the legal basis for thousands of future lawsuits alleging links to non-Hodgkin lymphoma. The company has set aside provisions of €11.8 billion for litigation, the majority related to this product.

While the legal battle looms, the operational front shows some stability. Chief Operating Officer Sebastian Guth confirmed on April 7th that newly announced U.S. import tariffs on pharmaceuticals require no change to the company's outlook. Under a U.S.-EU trade agreement, tariffs on most European goods, including medicines, are capped at 15%, a factor already incorporated into planning. Bayer is maintaining its 2026 EBITDA forecast of between €9.6 billion and €10.1 billion.

The month is packed with pivotal events for shareholders. A virtual Annual General Meeting is set for April 24th. Key agenda items include the election of Marcel Smits and Alfred Stern as new Supervisory Board members, replacing Paul Achleitner and Colleen Goggins. Investors will also vote on an unchanged dividend of €0.11 per share, payable on April 29th.

The immediate aftermath of the Supreme Court hearings will be scrutinized when Bayer releases its first-quarter results on May 12th. These figures are expected to include management's initial assessment of the proceedings. Another critical deadline follows on June 4th, which marks the cutoff for plaintiffs to opt out of a nationwide class settlement announced in February. Bayer has reserved the right to terminate this agreement if participation is too low.

Amid these headwinds, the pharmaceutical division is reporting progress. The eye drug Eylea 8 mg secured an additional approval in Japan, and the heart failure treatment Kerendia was approved in the EU based on a Phase III study involving around 6,000 patients. Looking further ahead, management is targeting mid-single-digit sales growth from 2027 onward and an operating margin of around 30 percent by 2030, supported by a new operating model designed to deliver €2 billion in savings.

The outcome of the Supreme Court case, expected by summer, will determine if Bayer can permanently cap its largest legal liability. Until then, the company navigates a billion-euro balancing act between operational guidance and existential legal risk.